{"id":3651,"date":"2011-03-21T09:38:34","date_gmt":"2011-03-21T13:38:34","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=3651"},"modified":"2011-03-21T09:38:34","modified_gmt":"2011-03-21T13:38:34","slug":"clinical-trial-underway-for-seasonalh1n1-vaccine","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=3651","title":{"rendered":"Clinical Trial Underway for Seasonal\/H1N1 Vaccine"},"content":{"rendered":"<p><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/Syringe_ZaldyImg_200.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-361\" title=\"Syringe_ZaldyImg_200\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/Syringe_ZaldyImg_200.jpg\" alt=\"Syringe (ZaldyImg\/Flickr)\" width=\"200\" height=\"197\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/Syringe_ZaldyImg_200.jpg 200w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/08\/Syringe_ZaldyImg_200-150x147.jpg 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/a><a href=\"http:\/\/www.medicago.com\/English\/news\/News-Releases\/News-ReleaseDetails\/2011\/Medicago-commences-US-phase-I-clinical-testing-of-its-H1N1--seasonal-vaccine1124557\/default.aspx\">Medicago Inc.<\/a>, a biotechnology company in Quebec City, Canada has begun a phase I clinical trial of its H1N1 influenza vaccine candidate in the United States. The trial tests the drug&#8217;s safety, tolerability, and capacity to induce an immune response, with results expected in three months.<\/p>\n<p>The randomized, double-blind, multicenter, active- and placebo-controlled dose-ranging study will evaluate a single dose of the H1N1 vaccine in 100 healthy adults 18-49 years of age. The subjects will be randomized to receive one of the following; an injection of the placebo, Medicago&#8217;s H1N1 vaccine, or an H1N1 vaccine from a licensed trivalent vaccine.<\/p>\n<p>Earlier this month, the World Health Organization and the U.S. Food and Drug Administration decided on the composition of the <a href=\"http:\/\/www.virology.ws\/2010\/03\/10\/trivalent-influenza-vaccine-for-the-2010-2011-season\/\">trivalent influenza virus vaccine<\/a> that will be used during the 2010-2011 season in the northern hemisphere. This phase I trial is expected to lead to Medicago&#8217;s next (phase 2a) trial in the U.S. for its seasonal trivalent vaccine with the recommended H1N1, H3N2, and B influenza strains, planned for later in 2011.<\/p>\n<p>The U.S. Centers for Disease Control and Prevention (CDC) recommends <a href=\"http:\/\/www.cdc.gov\/flu\/\">preventing seasonal flu<\/a> by getting a seasonal flu vaccination each year. According to CDC, each year in the United States on average, 5\u00a0 to 20 percent of the population gets the flu; on average, more than 200,000 people are hospitalized from flu-related complications, and; about 36,000 people die from flu-related causes.<\/p>\n<p>Read more:\u00a0<a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=639\">H1N1 Drug Gets Positive Results in Preclinical Tests<\/a><\/p>\n<p>Photo: <a href=\"http:\/\/www.flickr.com\/photos\/8499561@N02\/2755504975\/\">ZaldyImg\/Flickr<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medicago Inc., a biotechnology company in Quebec City, Canada has begun a phase I clinical trial of its H1N1 influenza vaccine candidate in the United States. The trial tests the drug&#8217;s safety, tolerability, and capacity to induce an immune response, with results expected in three months. The randomized, double-blind, multicenter, active- and placebo-controlled dose-ranging study [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15,5],"tags":[31,21,56,28,64,27],"class_list":["post-3651","post","type-post","status-publish","format-standard","hentry","category-products","category-regulations","tag-biomedical","tag-biotech","tag-canada","tag-clinical-trials","tag-life-sciences","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3651"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3651\/revisions"}],"predecessor-version":[{"id":3654,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3651\/revisions\/3654"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}